UAB Comprehensive Cancer Center Magazine Winter 2018 2018 Volume XXXIII Number 3 - Page 15

With HyperArc, which Varian Medical Systems tested and partly developed in collaboration with UAB, clinicians can deliver more compact radiation doses that closely conform to the size, shape and location of brain cancer tumors while sparing more surrounding healthy tissue. About 20-40 percent of cancer patients will develop brain metastases. More than half of them will have more than one tumor in the brain. The risk of a metastatic brain tumor depends on the kind of cancer and how advanced it is when it is diagnosed. Typically, an increasing number of patients return for retreatment of their disease. “HyperArc allows us to plan and deliver state-of-the-art radiosurgery to highly complex cases efficiently with a very high degree of dose compactness and conformity, and has made it possible to treat patients with larger numbers of brain metastases very aggressively,” says John Fiveash, M.D., professor and vice chair for academic programs in the UAB Department of Radiation Oncology. He is also a senior scient 7@BFRT"6&VV6fR66W"6VFW"( ĖFǒffR&F7W&vW'FVG2vW&PG&VFVBvFW$&2FW&FBf'7BF( ФG"ffV662( 7BbFW6RFVG2@VFR'&WF7F6W2vRvW&R&W76V@vFFRVƗGBVff6V7bFR7&VFBG&VFVBFVƗfW'FVG2&PW6FVBF&RG&VFVB&FR6B`R#֖WFW2vFWBFR&WV&VVBbখf6fR7FW&VF7F2VBg&R( ФW$&26F2&W67&FfRv&fpFB6VFW26VFwVFVƖW2FV@&ƗFG&VFVBrFV@6WGWvrB&RFWFW&֖VBFVƗfW'6WVV6R( ćW$&2w2W2F'&FFRVFPGV'2BFR6RFRvFWB&W6FpFRFVBv6&fFW2&WGFW"vVV@bFVBfVVBvR6frFRf"FPFVBBFR6Ɩ6FV( G"ffV662( &66ǒW$&22FW6vVBFV&P667FVBvVƗGrB6VW70R6Ɩ6FVƗfW'( 62&6&BRB&fW76"B767FBf6R6"f"672FRT"FW'FVBb&FF6wआR26WW'BfVG&VFVBpFV6VW2B6Ɩ6VVFFbWpFV6vW2B6V"66VF7BBFRT 6&VV6fR66W"6VFW"इW$&2FG&W76W266W&2&W@6WGFVB6fWG67BBV&W6W&6W2FB6R&F7W&vW'66W76&Pf"FVG2BVfV6&Rf"琦7FGWF2( v&r66VǒvFVFr7FGWF0ƖRT"VB'FB&RFPFWfVVBbW$&2( 62VVशVVG&W6FVBbf&( 26w77FV0'W6W72( vRfVRFV"6FVVB6G&'WF0FFRGf6VVBb66W"6&RBvR&PW6FVBFBW$&2G&VFVG2fRp&VwVFRR2( Ю( ćW$&2w0W2F'&FFPVFRGV'0BFR6PrF&VvFRv&fpf"FR7B6WfW&V'2T"2&VVv&rvFf&F'&rW$&0FV6wFg'VFT"2&VVffV@vFfW"FW"7FGWF2FWfVpF֗FF2FV6RFRF6R@G&VFVBFVƗfW'FWFWfVVBFVF6FV@v&F2FV7W&RVff6VBv&frBWrv2brBVFRF&vWG06VFVW6ǒvR&VGV6rFR6WGbFRr&6W72f"6Ɩ62FFFT"VVBFWf6RWG&72FW6Rf"6vR@VFRF&vWG2FB6&R7W7F֗VBFRvFW@&W6FrFPFVBv6&fFW2&WGFW vVV@bFV@fVVBvP6frFPf"FRFV@BFR6Ɩ6FV( Ф֗r67BBVff67( vR&R&RFV&RFVG2vFW@FRVVBFfW7BFFF"WpWVVB( G"R62W$&06FƗW2FRVVR6&ƗFW2bf&( 0G'VT&V(J"BTDt^(J"G&VFVB77FV2v6T"&VGW6W22rR"220( ffV6B&fW76"Bf6R6 f"6FV֖2&w&0FRT"FW"FV@b&FF6wR"RBR22R 0